Dupixent biosimilar (Chong Kun Dang Pharmaceutical)

N/A

Report date: 2026/02/09 20:01:27

Base Information

Drug NameDupixent biosimilar (Chong Kun Dang Pharmaceutical)
Drug Alias NameCKD-706
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin-13 inhibitorsInterleukin-4 inhibitorsInterleukin-4 receptor subunit alpha inhibitors
TargetsInterleukin-13Interleukin-4Interleukin-4 receptor subunit alpha
Therapy Area/IndicationsDermatitis, Atopic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermanyUnited Kingdom
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesChong Kun Dang Pharmaceutical Corp
China Registration ClassN/A

Develop Information

Active CompaniesChong Kun Dang Pharmaceutical Corp
Inactive CompaniesN/A
Active IndicationsDermatitis, Atopic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A